Neha Krishnamohan - Dec 1, 2022 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Role
Chief Financial Officer
Signature
/s/ Mark A. Meltz, as attorney-in-fact
Stock symbol
KNTE
Transactions as of
Dec 1, 2022
Transactions value $
-$11,307
Form type
4
Date filed
12/2/2022, 07:00 PM
Previous filing
Sep 6, 2022
Next filing
Feb 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNTE Common Stock Tax liability -$11.3K -1.46K -2.07% $7.75 69.1K Dec 1, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,543 shares acquired under the Issuer's Employee Stock Purchase Plan in November 2022.
F2 Includes 63,282 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date.